"Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label institutional investors. Show all posts
Showing posts with label institutional investors. Show all posts

Monday, June 15, 2026

Institutional investors recent "bought deal" is a very positive for Volatus Aerospace!

 



Updated Business / Investment Report

Volatus Aerospace (TSX: FLT)

Bought Deal Validation, Institutional Backing, Insider Alignment & the Rise of Canada’s Sovereign Drone Platform (June 2026) also:

On June 23rd, 2026,

Volatus Aerospace Opened it's brand new, 53,000-Square-Foot Mirabel Facility,

Establishing Domestic Manufacturing Base for Autonomous Defence Systems


Executive Summary

Volatus Aerospace is transitioning from a speculative drone-services company into what may become a strategically important Canadian aerospace/autonomy platform, positioned at the convergence of:

  • Canada’s sovereign defence buildout
  • NATO military modernization
  • autonomous cargo logistics
  • ISR (intelligence, surveillance & reconnaissance)
  • counter-drone systems (CUAS)
  • Arctic sovereignty
  • industrial aerial intelligence
  • AI-enabled aviation systems

The most important recent catalyst is the C$34.5M bought deal financing, which materially strengthens Volatus’ balance sheet, expands institutional sponsorship, and improves its ability to compete for larger sovereign/NATO contracts.

The central investment question is evolving from:

“Can Volatus survive?”

to:

“Can Volatus become Canada’s sovereign drone and autonomous logistics champion?”


1. The Bought Deal — Why It Matters More Than Many Investors Realize

🚨 June 2026 Bought Deal Financing

Volatus completed a C$34.5M bought deal public offering at C$0.65/share, issuing 53.13M shares, including the full exercise of the over-allotment option.

The Syndicate Matters

The deal was led by:

  • Desjardins Capital Markets (sole bookrunner)
  • Stifel Nicolaus Canada (co-lead)

with participation from:

  • Canaccord Genuity
  • Haywood Securities
  • Cormark
  • Ventum Financial
  • RBC Capital Markets
  • Scotia Capital.

Why This Is Important

For a micro/small-cap defence company:

institutional syndicate quality matters enormously.

This was not a weak retail financing.

The presence of RBC and Scotia is particularly notable because:

  • they generally avoid weak speculative financings
  • they improve institutional credibility
  • they can broaden future investor access

Perhaps most importantly:

the over-allotment was fully exercised.

That typically signals:

stronger demand than expected.


2. Institutional Investors — Why This Changes the Story

Although Volatus has not publicly disclosed the end-buyers yet, the structure strongly suggests:

Increasing Institutional Participation

Likely participants include:

  • Canadian small-cap funds
  • aerospace/industrial investors
  • growth institutions
  • family offices
  • defence-themed investors

Collectively, the bought-deal participants likely now control:

roughly 7–8% of the company post-financing.

Why This Matters

Institutional investors bring:

✔ longer holding periods
✔ capital-market credibility
✔ analyst attention
✔ improved liquidity
✔ easier future fundraising

Most importantly:

institutional investors often arrive before major re-ratings.

If future filings reveal:

  • defence-focused funds
  • pension involvement
  • aerospace specialists

the investment thesis strengthens materially.


3. Insider Behaviour — One of the Strongest Signals

One of the most encouraging aspects of Volatus today is:

insiders continue to hold and invest, rather than aggressively sell.

For speculative growth companies, insider behavior matters.

What investors normally fear:

  • insider selling
  • excessive option liquidation
  • “story stock” management exits

Instead, Volatus insiders have:

✔ remained heavily aligned
✔ retained meaningful ownership
✔ continued long-term positioning

Why this matters:

When management continues holding through dilution and volatility, it usually signals:

confidence in long-term value creation.

That does not guarantee success.

But it improves alignment between:

shareholders and leadership.

 For instance...

Founder/CEO Glen Lynch owns a very substantial equity position — in excess of ~68 million shares (directly and indirectly controlled) based on recent company disclosures and investor materials. While the exact number fluctuates due to financings, RSUs, warrants, and corporate transactions,.

With 35 years experience in the Aerospace industry, dealing with Government agencies and other Aerospace entities, this insider ownership alone, speaks volumes about what is becoming a great investment opportunity.


4. Technology Stack — Why Volatus Is More Than “A Drone Company”

Volatus increasingly resembles a:

full-stack aerial autonomy platform

rather than simply a drone operator.

Its technology portfolio is becoming highly aligned with NATO and sovereign defence needs.


🚨 SKYDRA™ — Counter-Drone Software Platform

Launched in 2026, SKYDRA is Volatus’ first SaaS defence platform for:

  • counter-drone planning
  • CUAS simulations
  • mission rehearsal
  • operational readiness

Target users:

  • NATO militaries
  • airports
  • energy infrastructure
  • ports
  • governments
  • critical infrastructure operators.

Strategic importance:

Modern warfare increasingly requires:

defending against hostile drones.

Ukraine demonstrated:

drones are cheap; defending against them is mandatory.

SKYDRA could become:

a recurring software revenue engine.

This is important because...

 software businesses receive far higher valuation multiples than hardware operators.


✈️ Autonomous VTOL Cargo Drone Platform

Through its partnership with Dufour Aerospace, Volatus is commercializing:

hybrid-electric autonomous VTOL cargo systems.


Key advantages:

✔ no runway required
✔ autonomous operation
✔ Arctic capable
✔ offshore logistics
✔ military resupply potential

NATO relevance:

This technology directly addresses:

one of NATO’s biggest logistics problems:

moving supplies into:

  • remote areas
  • contested zones
  • Arctic environments

without risking pilots.

Applications include:

Defence

  • Arctic sovereignty
  • NATO logistics
  • battlefield resupply
  • ISR support

Commercial

  • mining
  • oil & gas
  • offshore wind
  • emergency medicine
  • remote communities

This is an underappreciated opportunity.


🛰️ SWITCH Prime ISR Platform

Volatus’ SWITCH Prime UAV is built for:

  • long-range surveillance
  • ISR missions
  • border security
  • Arctic monitoring
  • infrastructure inspection.

Why this matters:

Canada’s defence priorities increasingly emphasize:

Arctic domain awareness.

SWITCH Prime fits directly into:

  • border monitoring
  • maritime awareness
  • NATO surveillance

🎯 ASCENT SPIRIT Tactical UAV

The ASCENT SPIRIT system supports:

  • tactical ISR
  • persistent monitoring
  • perimeter defence
  • mission-critical surveillance.

Its modular architecture allows:

✔ payload flexibility
✔ autonomous navigation
✔ rugged deployment

This aligns directly with:

modern battlefield autonomy doctrine.


5. Why Canada & NATO Matter So Much to Volatus

The biggest investment variable remains:

Will Canada make Volatus strategically important?

Canada’s defence strategy increasingly emphasizes:

✔ sovereign manufacturing
✔ domestic autonomy systems
✔ Arctic defence
✔ ISR capability
✔ counter-UAS readiness.

Volatus already possesses:

  • operational infrastructure
  • pilots
  • drone operations
  • BVLOS approvals
  • training systems
  • manufacturing initiatives
  • autonomous software
  • defence advisory leadership.

This makes Volatus one of the few publicly traded Canadian companies already positioned for that shift.


6. Financial Progress — Still Early, But Improving

Q1 2026 showed:

Positive developments:

record Q1 gross margins (35%)
✔ stronger operational efficiency
✔ improved liquidity position
✔ defence investment accelerating.

Risks remain:

⚠ still loss-making
⚠ dilution risk
⚠ contract timing risk
⚠ scaling execution risk.

This remains:

a venture-style investment.


Final Investment Assessment

The recent bought deal substantially changes the Volatus story.

Before:

speculative undercapitalized drone company.

Increasingly now:

institutionally financed sovereign aerospace/autonomy platform.

The combination of:

  • stronger balance sheet
  • institutional sponsorship
  • insider alignment
  • autonomous cargo systems
  • defence software (SKYDRA)
  • ISR technology
  • NATO positioning
  • sovereign Canadian defence alignment

creates a materially stronger investment thesis than existed even 12 months ago.

The opportunity is substantial!

But execution still determines whether FLT becomes:

Canada’s sovereign drone/autonomous defence champion! 



Thursday, September 25, 2025

Today, I revisited BEAM Therapeutics and noted institutional investors increasing their positions! Here's the lowdown!

Quite a few funds besides Peregrine (17% this month) boosted their positions in BEAM Therapeutics in the last ~3 months. 

The biggest disclosed step-ups were by FMR LLC (Fidelity) and ARK Investment Management, both via fresh 13G/A filings in August 2025. I’ve also included several smaller 13F increases.




Notable increases in the past ~3 months

  • FMR LLC (Fidelity) filed a 13G/A on Aug 6, 2025, lifting its stake to 15.00% (15,083,498 sh)—a large increase from prior. Fintel

  • ARK Investment Management filed a 13G/A on Aug 7, 2025, lifting to 10.35% (10,410,137 sh). Fintel

  • Legal & General Group Plc (13F, filed Aug 12, 2025) reported 102,646 sh, up +8.48% q/q. Fintel

  • VanEck Associates (13F, filed Aug 14, 2025) reported 1,451 sh, up +11.27% (tiny but technically an increase). Fintel

  • AMG National Trust Bank (13F, filed Aug 4, 2025) reported 17,007 sh, up +289% q/q. Fintel

(And yes, Peregrine Investment Management disclosed a +17.8% increase (to 264,260 sh) in its latest 13F, covered by MarketBeat on Sept 24, 2025. ) MarketBeat

Note: 13G/A stakes (FMR, ARK) are the cleanest % of shares-out data. 13F changes indicate direction q/q but do not include exact ownership % of the company and lag by up to ~45 days.

“All” institutional investors & their % stakes

There are roughly ~455 institutional holders on record for BEAM. Publishing all of them (with % stakes) doesn’t fit here, but below are the principal holders with the best available % figures from recent filings. For >5% owners, I use the 13G/A numbers (most authoritative for company %); for others I cite aggregated holder pages that estimate % of shares outstanding.

Top institutional holders (latest reported % of shares outstanding):

  • FMR LLC (Fidelity)15.00% (13G/A, Aug 6, 2025). Fintel

  • ARK Investment Management LLC10.35% (13G/A, Aug 7, 2025). Fintel

  • Farallon Capital Management~9.99% (13G/A, May 13, 2025; still current in Fintel roster). Fintel

  • The Vanguard Group, Inc.~9.88% (aggregator snapshot). Investing.com

  • BlackRock, Inc.~8.14% (aggregator snapshot). Investing.com

  • State Street Global Advisors~3.70% (aggregator snapshot). Investing.com

  • Arch Venture Partners~4.62% (aggregator snapshot; also on Fintel 13D/G roster). Investing.com+1

  • Amova Asset Management~4.81% (aggregator snapshot). Investing.com

  • Farallon Healthcare Partners~5.87% (aggregator snapshot). Investing.com

  • Bellevue Asset Management~2.94% (aggregator snapshot). Investing.com

  • T. Rowe Price Group~2.49% (aggregator snapshot). Investing.com

For the full institutional roster (hundreds of entries) with adds/cuts and effective dates, Fintel’s BEAM ownership page is the most complete live index and shows both the headline owner count (~455) and recent filings; many details beyond the top tier are behind their login/paywall. Fintel

Ed Note:

We have also increased our position in BEAM in September!

Related Articles:

BEAM Therapeutics getting closer to FDA approvals for cutting edge therapies


Friday, September 19, 2025

Cabaletta Bio $CABA might just be that "needle in the haystack" of Microcap BioTechs poised for greater things

  • Here’s a fresh, single-page style investment/business report on Cabaletta Bio (NASDAQ: CABA) that pulls in the August–September 2025 filings, company updates, and the latest clinical/CMC details. 


    1) Institutional holders — latest Schedule 13G/13G-A cluster (summer 2025)

    Notes: figures below come from each filer’s Schedule 13G/13G-A (event date generally June 30, 2025; filings landed Aug 6–14, 2025, unless noted). Do not add Prudential (PFI) on top of Jennison (PFI is the parent; overlapping exposure). Percentages use each filer’s own denominator and blocker math where applicable.

    Holder (form)Reported shares / power% of classFiled
    Jennison Associates LLC (IA)10,107,1677.2%Aug 6, 2025. Cabaletta Bio, Inc.
    Alyeska Investment Group, L.P. (+ GP & Anand Parekh)8,904,367 (shared vote/dispo; includes warrants)9.9%Aug 14, 2025. Cabaletta Bio, Inc.+1
    Bain Capital Life Sciences Opportunities III, L.P.9,677,125 (incl. exercisable portion of warrants; 9.99% blocker)9.99%Aug 14, 2025. Cabaletta Bio, Inc.+1
    Adage Capital (ACM/ACP; Gross & Atchinson)9,002,580 (incl. 172,822 via warrants)9.99%Aug 12, 2025. Cabaletta Bio, Inc.+2Cabaletta Bio, Inc.+2
    Citadel (Advisors entities & Securities)≈4.69M aggregated (shared vote/dispo)n/aJun 20, 2025. SEC
    Cormorant Asset Management, LP5,000,000 (shared vote/dispo)5.47% (filer calc.)Aug 14, 2025. Stock Titan
    Prudential Financial, Inc. (umbrella for Jennison/PGIM)10,391,167 consolidated7.4%Aug–Sep 2025. (Umbrella disclosure; overlaps Jennison.) Stock Titan
    Vanguard Group, Inc.3,450,7273.83%Jul 29, 2025. Stock Titan
    BlackRock, Inc.894,647~1.0%Jul 16, 2025. Stock Titan
    (Reference) Company’s SEC page with the full August clusterAug–Sep 2025. Cabaletta Bio, Inc.

    Read-through: Multiple sophisticated, crossover/hedge funds sit near ~10% positions (often with warrants and 9.99% blockers). The concentration provides liquidity/support but also means the cap table can react quickly to data/financing.


    2) Financials & operating posture (latest reported)

    • Cash & securities: $194.7M at June 30, 2025; company guides runway into 2H 2026. Cabaletta Bio, Inc.+1

    • Burn snapshot: Q2’25 disclosure highlights elevated R&D as registrational prep ramps; (press summary cites R&D ~$37.6M for Q2’25). Stock Titan

    • Capital markets actions: Public offering priced June 11, 2025 (~$100M gross) to extend runway and prep commercial readiness. Cabaletta Bio, Inc.

    • Option repricing (May 2025): Board repriced all outstanding options under 2018/2019 plans to $1.92 (close on May 19, 2025); other terms unchanged; disclosed via 8-K and insider Form 4 footnotes. SEC+3Cabaletta Bio, Inc.+3Cabaletta Bio, Inc.+3


    3) Technology, clinical status & CMC

    • Modality: Autologous CD19 CAR-T (rese-cel / CABA-201) for autoimmune disease (RESET program: myositis, SLE/LN, systemic sclerosis; also MG & PV studies).

    • Regulatory path: After FDA alignment, company targets a 2027 BLA in myositis; two registrational cohorts (~15 pts each) added to RESET-Myositis (H2’25 start). Cabaletta Bio, Inc.+1

    • Signal recap (EULAR 2025): In myositis, 7/8 patients achieved clinically meaningful TIS responses after discontinuing all immunomodulators and while off/tapering steroids; durability maintained across follow-up in responders. Broader 18-patient dataset (Myositis/SLE/SSc) presented across three orals. Cabaletta Bio, Inc.+1

    • CMC & scale-up: Viral vector Oxford Biomedica; drug product process transferred to Lonza for registrational enrollment; 424B5 also references broader manufacturing network/tech transfer steps. Cabaletta Bio, Inc.+1

    • Fresh materials: Corporate Presentation (Sept 3, 2025) furnished via 8-K; good for latest timelines and site maps. Cabaletta Bio, Inc.+1


    4) Share-price outlook (2–4 years) — scenario framing

    (Not investment advice; illustrative ranges hinge on efficacy durability, safety, enrollment speed, CMC, and financing.)

    • Bull case (approval path visible): Registrational myositis cohorts reproduce early magnitude/durability with manageable CRS/ICANS; CMC runs clean; payer dialogues constructive. A first-wave autoimmune CAR-T approval narrative can support multi-$bn EV on commercialization math. Catalysts: registrational updates through 2026; BLA prep in 2027. Cabaletta Bio, Inc.+1

    • Base case (solid but mixed): Positive efficacy with some variability; modest timeline slippage; 1–2 additional financings pre-BLA. Stock tracks data cadence and dilution quality. Cabaletta Bio, Inc.

    • Bear case (execution/safety/CMC issues): Durability or safety setbacks in larger N, or CMC friction → regulators request more data; financing at discounts. Shares trade on runway/option value until de-risking. Cabaletta Bio, Inc.

    12–24 mo. watch-items: Registrational cohort initiation/readouts; ≥6–12-mo durability in responders; neurotoxicity/CRS profile with larger N; Lonza/Oxford readiness and yields; net burn vs runway. Cabaletta Bio, Inc.


    5) Takeover potential & likely interested acquirers

    Is CABA a takeout candidate? Plausible in 12–24 months if registrational myositis data are convincingly positive and safety/CMC are on track. (There is no public report of active talks; this is strategic inference.)

    Most logical buyers (fit rationales):

    • Big Immunology owners: AbbVie, J&J, Roche, Sanofi, GSK — deep autoimmune franchises; acquiring a “one-and-done” CD19 CAR-T for autoimmunity would hedge biologic erosion and extend leadership.

    • Cell-therapy leaders: Novartis, BMS, Gilead — existing CAR-T manufacturing/logistics; diversification from oncology to autoimmunity.

    • Large biotechs seeking autoimmune depth: AstraZeneca, Regeneron — platform integration plus commercial muscle.

    Signals to monitor: expanded CMC partnerships, structured ex-US deals, banker/advisor hires, unusual block trades, and headline registrational efficacy/safety that de-risks approval.


    6) Key risks (what can break the thesis)

    • Clinical & safety: Autoimmune CAR-T in larger populations is still early; durability and neurotoxicity risk (ICANS) must remain acceptable as N scales; breadth of evidence may be required by regulators. Cabaletta Bio, Inc.

    • Manufacturing & cost-to-serve: Autologous CAR-T economics and logistics vs chronic SOC; execution with Lonza/Oxford is critical for registrational and early commercial phases. Cabaletta Bio, Inc.

    • Financing/dilution: Runway to 2H’26 implies further capital likely ahead of BLA; option repricing aligned incentives but may be viewed as shareholder-unfriendly. Cabaletta Bio, Inc.+1


    Appendices / source links

    • SEC Filings hub (CABA) — latest 8-K (Sept 3, 2025), DEF 14A (May 13, 2025), Q2’25 10-Q links. Cabaletta Bio, Inc.

    • Q2’25 results PR (Aug 7, 2025) — cash/runway, registrational plan, EULAR data summary, CMC partners. Cabaletta Bio, Inc.+1

    • EULAR 2025 itemized data (Company 8-K & PR)7/8 TIS responders off immunomodulators; 18-patient dataset across Myositis/SLE/SSc. Cabaletta Bio, Inc.

    • Manufacturing — Oxford Biomedica (vector), Lonza (drug product) in Q2’25 PR; broader manufacturing/TT in 424B5. Cabaletta Bio, Inc.+1

    • Institutional holdersBain 13G/A (Aug 14), Adage 13G/A (Aug 12), Alyeska 13G (Aug 14), Jennison 13G (Aug 6), Citadel 13G (Jun 20), Vanguard/BlackRock updates; umbrella PFI. Stock Titan+7Cabaletta Bio, Inc.+7SEC+7

    • Option repricing — Company 8-K (May 15, 2025) and insider Form 4 footnotes (effective May 19, 2025; reset to $1.92). Cabaletta Bio, Inc.+2Cabaletta Bio, Inc.+2

    • Corporate Presentation (Sept 2025) — furnished via 8-K and posted to IR site. Stock Titan+1


    Bottom line

    Cabaletta has a clear myositis BLA path (2027), supportive EULAR 2025 signals, credible CMC partners, and a cap table populated by sophisticated ~10% holders. Over the next 12–24 months, registrational efficacy/safety + CMC execution will determine whether CABA becomes (a) a high-value independent launch story, or (b) a logical take-out for a large immunology or CAR-T incumbent.

  • Ed Note: we are long CABA stock! 


    🔍 Current Analyst Price Targets

    SourceAvg / Consensus TargetHigh / LowNotes
    FintelUS$11.79 one-year targetHigh $23.10, Low $2.02 Fintel
    StockAnalysisUS$12.75 averageHigh $25, Low $2 StockAnalysis
    MarketWatch / ZacksUS$11.56 average / median ~ US$14.00Low ~US$2.00, High ~US$22.00 MarketWatch+1
    TipRanksUS$12.00 averageHigh ~US$22.00, Low ~US$2.00 TipRanks
    StocksGuideUS$14.28 average among ~11 analystsHigh ~$23.10, Low ~$2.02 StocksGuide
    MarketBeatUS$14.50 consensusBased on 7 buy ratings, 1 hold; upside from current ~$2.18 price MarketBeat

    💡 What This Implies

    • The consensus range is roughly US$11-$15 under most recent coverage, with outliers up to high-teens or low-$20s in bullish analyst models.

    • The lowest targets are in the $2-$3 range, reflecting some analysts factoring in risk of execution, safety / durability issues, or maybe skeptical timelines.

    • The average upside is very large (several hundred percent) from current share price (~US$2) under many forecasts — which suggests analysts believe a lot of the potential is not yet priced in.


    ⚙️ Caveats & Reliability

    • Volatility & data risk: Because CABA is clinical-stage, much depends on upcoming data (registrational cohorts, safety, durability). A miss could shift expected targets downward sharply.

    • Wide ranges indicate uncertainty: The $2 lows are likely “if everything goes poorly or delays mount”; the $22+ highs assume strong execution, regulatory alignment, and favorable commercial environment.

    • Time horizon: These are mostly 12-month targets; some assume BLA/registrational success is de-risked sooner. If delays happen, the target may shift.

    • Analyst bias: Some high targets come from firms with more bullish biotech portfolios; they may assume best-case outcomes. Check which analysts have been conservative vs optimistic in similar names.